Bio-Rad Laboratories faced a significant setback, reporting a net loss of $527 million in Q1 2026, severely missing earnings expectations of $2.77 per share. The company's revenue of $592.1 million reflects only a 1.2% increase from the previous year, hindered by an $11 million diagnostic disruption and external pressures from the Middle East conflict. Looking ahead, Bio-Rad forecasts stagnant currency-neutral revenue growth between -3% and +0.5% for the year, with stock ratings currently advising a sell as recovery efforts continue.
“Bio-Rad Laboratories Inc · reported Q1 results · within their revenue guidance · despite external pressures”
“Middle East conflict · created · outsized headwind · for Bio-Rad”
“Bio-Rad · expects · 2026 currency-neutral revenue growth · between -3% and +0.5%”
“Bio-Rad · quantified · diagnostic disruption · $11 million”
“Bio-Rad reported · a net loss of · $527 million · for Q1 2026”
“Bio-Rad has spent · to repurchase · 2.1 million shares · $542 million”
“Bio-Rad Laboratories · reported quarterly earnings of · $1.89 per share · missing the Zacks Consensus Estimate of $2.77 per share”
“Bio-Rad Laboratories · had earnings of · $2.54 per share · a year ago”
“Bio-Rad Laboratories · experienced an earnings surprise of · -31.77%”
“Bio-Rad Laboratories · was expected to post earnings of · $2.57 per share · but actually produced $2.51 per share, delivering a surprise of -2.33%”
“Bio-Rad Laboratories · surpassed consensus EPS estimates · once · over the last four quarters”
“Bio-Rad Laboratories · posted revenues of · $592.1 million · for the quarter ended March 2026”